Analysts Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Target Price at $29.50

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has been given a consensus rating of “Moderate Buy” by the eleven brokerages that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $29.50.

A number of brokerages have recently weighed in on FDMT. Chardan Capital reiterated a “buy” rating and set a $25.00 price target on shares of 4D Molecular Therapeutics in a research report on Tuesday, August 12th. Royal Bank Of Canada reiterated an “outperform” rating and set a $26.00 price target on shares of 4D Molecular Therapeutics in a research report on Tuesday, October 21st. Roth Capital dropped their price target on 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating on the stock in a research report on Tuesday, August 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, October 8th.

4D Molecular Therapeutics Trading Down 0.8%

Shares of 4D Molecular Therapeutics stock opened at $11.32 on Tuesday. The business’s 50 day simple moving average is $8.39 and its 200-day simple moving average is $5.68. The stock has a market capitalization of $528.64 million, a price-to-earnings ratio of -3.21 and a beta of 2.93. 4D Molecular Therapeutics has a twelve month low of $2.23 and a twelve month high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.98) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.10). The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.52 million. 4D Molecular Therapeutics had a negative return on equity of 40.15% and a negative net margin of 594,375.81%. Sell-side analysts predict that 4D Molecular Therapeutics will post -2.84 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Scott Bizily sold 2,678 shares of the firm’s stock in a transaction that occurred on Friday, October 24th. The stock was sold at an average price of $12.00, for a total value of $32,136.00. Following the sale, the insider directly owned 3,594 shares in the company, valued at $43,128. This trade represents a 42.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders sold 9,128 shares of company stock valued at $92,100. 9.60% of the stock is owned by company insiders.

Institutional Trading of 4D Molecular Therapeutics

Several large investors have recently added to or reduced their stakes in FDMT. Dynamic Technology Lab Private Ltd acquired a new stake in 4D Molecular Therapeutics in the 1st quarter valued at approximately $39,000. Y Intercept Hong Kong Ltd acquired a new stake in 4D Molecular Therapeutics in the 1st quarter valued at approximately $41,000. Los Angeles Capital Management LLC acquired a new stake in 4D Molecular Therapeutics in the 2nd quarter valued at approximately $42,000. Quadrature Capital Ltd acquired a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter worth approximately $42,000. Finally, Farther Finance Advisors LLC lifted its stake in shares of 4D Molecular Therapeutics by 117.4% in the 3rd quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock worth $43,000 after acquiring an additional 2,674 shares during the period. 99.27% of the stock is currently owned by institutional investors and hedge funds.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.